Bank Of Montreal Lineage Cell Therapeutics, Inc. Transaction History

Bank Of Montreal

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$1.84 - $2.68 $661,261 - $963,141	-359,381 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$2.26 - $2.86 $44,521 - $56,342	-19,700 Reduced 5.2%	359,381 $913,000
Q2 2021 Aug 12, 2021	BUY	$2.17 - $3.0 $822,605 - $1.14 Million	379,081 New	379,081 $1.11 Million

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $96.8M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.